There is a growing scarcity of novel and effective broad-spectrum antibiotics for the treatment of bacterial infections.
Slide to view more
*Paratek has global rights with the exception of the greater China region where Paratek has entered into a collaboration agreement with Zai Lab (Shanghai) Co., Ld.
Antimicrobial Resistance (AMR) is life-threatening, costly and present in every country in the world.
Drug-resistant infections cost the US an annual $20 billion in excess healthcare costs and $35 billion in lost productivity. According to recent research, it's estimated that up to 160,000 in US die from antibiotic resistance per year and almost three-quarters of a million people around the globe annually; by 2050 that could grow to 10 million every year if the trend isn’t slowed.
Paratek is fighting the AMR pandemic.
.webp)
NUZYRA® (omadacycline), approved by the FDA, is a once-daily oral and intravenous antibiotic for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by select susceptible microorganisms. See Full Prescribing Information here.
Paratek remains committed to the further study of NUZYRA in additional areas on unmet medical need. For a full list of ongoing clinical studies, please visit clinicaltrials.gov.
Under a broad-based Project BioShield contract with Biomedical Advanced Research and Development Authority, or BARDA, which is a part of the United States Department of Health and Human Services and the Office of the Assistant Secretary for Preparedness and Response, NUZYRA® is being studied against anthrax, a pathogenic agent that potentially causes an infectious disease of public health and biodefense importance.
Paratek owns world-wide rights to omadacycline. Paratek has entered into a collaboration with Zai Lab (Shanghai) Co., Ltd., to support the development and commercialization of omadacycline for patients in Greater China.
Learn more about NUZYRA® including important safety information.
The FDA approved SEYSARA® (sarecycline) in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. SEYSARA® is marketed by Almirall, LLC in the U.S. For complete prescribing information, including the Warnings and Precautions, please visit here.
Almirall, LLC owns the rights to sarecycline and is currently exploring partnership opportunities to develop and approve sarecycline in appropriate markets. For information, please visit here (Contact Us | Almirall).
Interested in partnerships for rights to Nuzyra in other regions. Please contact us at 617-807-6600 or at info@paratekpharma.com and you will be directed to our Business Development Team.
Click here to learn more about prescribing NUZYRA® to your patients.
Download
